Veraxa Biotech Holding AG
Limited financial coverage for VRXA.
Not enough data to compute a meaningful composite — typical for foreign-listed ADRs, recent IPOs, or thinly-covered small caps. Live quote, chart, and any available stats still render below.
About the company
Veraxa Biotech Holding AG is a clinical-stage biopharmaceutical company, formed via a merger with Voyager Acquisition Corp., focusing on developing next-generation cancer therapies such as antibody-drug conjugates (ADCs) and bispecific T-cell engagers. [64, 65]
- CEO
- Christoph Antz
- IPO
- 2026
- Employees
- 8
- HQ
- Heidelberg, ZH, DE
Price Chart
Get TickerSpark's AI analysis on VRXA
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
- 52W High
- $27.36
- 52W Low
- $1.70
- 50D MA
- $8.28
- 200D MA
- $10.30
- Beta
- 0.25
- Avg Volume
- 385.17K
Our VRXA coverage
Recent articles, reports, and earnings notes.
Want a deeper read on VRXA?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.